Waag D M, England M J, Pitt M L
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011, USA.
Vaccine. 1997 Nov;15(16):1779-83. doi: 10.1016/s0264-410x(97)00107-2.
Q fever is an acute and self-limited febrile illness caused by the obligate intracellular bacterium Coxiella burnetii. While phase I cellular Q fever vaccines are efficacious in humans, vaccination of immune individuals may result in sterile abscesses and granulomas. The chloroform:methanol residue vaccine (CMR) was developed as a safer alternative. The efficacy of a licensed phase I cellular vaccine (Q-Vax) was compared with that of CMR vaccine in A/J mice and Hartley guinea pigs challenged with virulent phase I C. burnetii by aerosol. Both vaccines were efficacious. The CMR vaccine dose required to protect 50% of mice (PD50) against lethal aerosol challenge (11 LD50) was one-third of the Q-Vax dose. However, the PD50 for CMR was four times the Q-Vax dose in guinea pigs challenged by aerosol (60 LD50). It was concluded that CMR is an efficacious alternative to cellular Q fever vaccines for the prevention of Q fever.
Q热是一种由专性细胞内细菌伯氏考克斯体引起的急性自限性发热性疾病。虽然I期细胞Q热疫苗对人类有效,但免疫个体接种疫苗可能会导致无菌性脓肿和肉芽肿。氯仿:甲醇残留疫苗(CMR)作为一种更安全的替代品而被研发出来。在通过气溶胶感染强毒I期伯氏考克斯体的A/J小鼠和Hartley豚鼠中,将一种已获许可的I期细胞疫苗(Q-Vax)的效力与CMR疫苗的效力进行了比较。两种疫苗均有效。保护50%的小鼠(PD50)免受致死性气溶胶攻击(11 LD50)所需的CMR疫苗剂量是Q-Vax剂量的三分之一。然而,在通过气溶胶攻击(60 LD50)的豚鼠中,CMR的PD50是Q-Vax剂量的四倍。得出的结论是,CMR是预防Q热的细胞Q热疫苗的一种有效替代品。